I've never understood are obsession with mRNA. I swear its success isn't from being better, but from being enough of a buzzword to getting extra funding and exceptions. There's no reason Corbevax wouldn't have had the same speedy development as Comirnaty and Spikevax, if it were treated the same, and logistically it's a much better product.
I've never understood are obsession with mRNA. I swear its success isn't from being better, but from being enough of a buzzword to getting extra funding and exceptions. There's no reason Corbevax wouldn't have had the same speedy development as Comirnaty and Spikevax, if it were treated the same, and logistically it's a much better product.